Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Velleca Mark A.
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Yurasov Sergey
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Buck Elizabeth
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Jones Erika
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Hatzis-Schoch Brent
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Behbahani Ali
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Raman Prakash
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Campbell Shannon
Black Diamond Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-T. Rowe Price Investment Management, Inc.(19.0%)
Black Diamond Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Vestal Point Capital, LP(8.9%),Ryan Wilder(8.9%)
Black Diamond Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(6.2%)
Black Diamond Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(6.2%)
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Behbahani Ali
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Campbell Shannon
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Raman Prakash
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-10% Owner Versant Venture Capital VI, L.P.
Black Diamond Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Versant Ventures VI GP, L.P.(7.7%),Versant Ventures VI GP-GP, LLC(7.7%), etc.
Black Diamond Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-T. Rowe Price Investment Management, Inc.(18.9%)
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Behbahani Ali
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Raman Prakash